Antibiotic Resistance associated with the COVID-19 Pandemic: A Rapid Systematic Review

Langford BJ, Public Health Ontario Soucy J-PR, Dalla Lana School of Public Health, University of Toronto Leung V, Public Health Ontario, Toronto East Health Network So M, University Health Network, University of Toronto Kwan ATH, MSc, Department of Chemical & Physical Sciences, University of Toronto (angela.kwan@mail.utoronto.ca) Portnoff JS, HBSc, Faculty of Medicine, University of Queensland (j.portnoff@uq.edu.au) Bertagnolio, S, World Health Organization Raybardhan S, North York General Hospital MacFadden D, The Ottawa Hospital, University of Ottawa Daneman N, Public Health Ontario, Sunnybrook Health Sciences Centre, University of Toronto

1

Abstract

Background: COVID-19 and antimicrobial resistance (AMR) are two intersecting global public health crises.

Objective: We aim to describe the impact of the COVID-19 pandemic on AMR across healthcare settings.

Data Source: A search was conducted in December 2021 in World Health Organization's COVID-19 Research Database with forward citation searching up to June 2022.

Study Eligibility: Studies evaluating the impact of COVID-19 on AMR in any population were included and influencing factors were extracted.

Methods: Pooling was done separately for Gram-negative and Gram-positive organisms. Random effects meta-analysis was performed.

Results: Of 6036 studies screened, 28 were included and 23 provided sufficient data for meta-analysis. The majority of studies focused on hospital settings (n=25, 89%). The COVID-19 pandemic was not associated with a change in the incidence density (IRR 0.99, 95% CI: 0.67 to 1.47) or proportion (RR 0.91, 95% CI: 0.55 to 1.49) of MRSA or VRE cases. A non-statistically significant increase was noted for resistant Gramnegatives (i.e., ESBL, CRE, MDR or carbapenem-resistant *Pseudomonas* or *Acinetobacter* species, IRR 1.64, 95% CI: 0.92 to 2.92; RR 1.08, 95% CI: 0.91 to 1.29). The absence of enhanced IPAC and/or ASP initiatives was associated with an increase in Gram-negative AMR (RR 1.11, 95%CI: 1.03 to 1.20), while studies that did report implementation of these initiatives noted no change in Gram-negative AMR (RR 0.80, 95%CI: 0.38 to 1.70). However, a test for subgroup differences showed no statistically significant difference between these groups (P=0.40)

Conclusion: The COVID-19 pandemic could play an important role in the emergence and transmission of AMR, particularly for Gram-negative organisms in hospital settings. There is considerable heterogeneity in both the AMR metrics utilized and the rate of resistance reported across studies. These findings reinforce the need for strengthened infection prevention, antimicrobial stewardship, and AMR surveillance in the context of the COVID-19 pandemic.

PROSPERO registration: CRD42022325831

This research was carried out as part of routine work, no funding was received Data collection template, data, and analytic code are available upon request.

Background

High antibiotic use in patients with COVID-19 threatens to contribute to the antimicrobial resistance crisis. Although antibiotics do not treat COVID-19, they are commonly used because of initial diagnostic uncertainty in patients presenting with respiratory illness, and of concern for bacterial co-infection or secondary infection in those with confirmed COVID-19. We performed a series of rapid reviews as part of a living review on concomitant bacterial infection in the context of COVID-19 and found high antibiotic prescribing (approximately 75%) despite the relatively low bacterial infection rates, particularly in patients outside of the ICU setting (<10%).^{1–3}

Our most recent systematic review identified COVID-19 patients as a potential important reservoir for antimicrobial resistance. Over 60% of patients with COVID-19 who had a bacterial infection were infected with a highly resistant organism.⁴ Due to person-to-person transmission of organisms, particularly in healthcare settings, this presents a threat to the broader population beyond those with COVID-19.

While substantial inappropriate antibiotic prescribing has occurred in patients with COVID-19, antibiotic use for other infectious syndromes has declined early in the pandemic, particularly in community settings.^{5,6} This could potentially be due to the attenuation of transmission of other viral and bacterial pathogens due to public health measures to contain COVID-19, including physical distancing and masking. Enhanced infection prevention and control activities in healthcare settings could further mitigate the impact on AMR.⁷ Given potentially opposing effects, it is unclear how selection of antibiotic resistance in bacteria has occurred across populations during the pandemic. Emerging data from the United States Centers for Disease Control and Prevention suggests the pandemic has resulted in rising rates of AMR, including carbapenemresistant *Acinetobacter* and extended spectrum beta-lactamase producing *Enterobacterales.*⁸

While we have reported that antimicrobial resistance is high in individual patients with COVID-19 and bacterial infection, the ecological impact of the pandemic on AMR at the population level is not yet well-described. We aim to describe the impact of the COVID-19 pandemic on antimicrobial resistance across healthcare settings.

Methodology

Searches

We performed a comprehensive search of the World Health Organization (WHO) COVID-19 Research Database for published literature in any language from January 1, 2019 to December 1, 2021 with assistance from medical library information specialists. The WHO COVID-19 Research Database is a comprehensive multilingual source of

COVID-19 literature updated weekly that includes citations from Medline, Scopus, CINAHL, ProQuest Central, Embase, and Global Index Medicus.⁹ The search strategy was structured to include co-infection or secondary infection terms and bacterial infection terms which were applied to the COVID-19 literature in the database. The full search strategy is available in the supplement. Forward citation searching was performed in Google Scholar to capture more recent publications up to June 2022.¹⁰

Study Eligibility

All studies in inpatient and outpatient settings were eligible for inclusion. The following inclusion and exclusion criteria were applied:

Inclusion Criteria

- 1. Study provides data on antibiotic resistance before (before January 2020, or as identified by authors) vs. during the COVID-19 pandemic (January 2020 or later, or as identified by authors) in a specific healthcare setting.
- Antibiotic resistance is reported as 1) incidence density rate (e.g., rate per 1000 patient days or per patient population), and/or 2) effect measure (e.g., risk, odds, rate ratio) of antimicrobial resistance, and/or 3) prevalence of antimicrobial resistant organisms (e.g., methicillin-resistant *Staphylococcus aureus* (MRSA) out of all Staphylococcus aureus).

Antibiotic resistance includes any of the following pathogens, as defined by study authors: MRSA, vancomycin-resistant *enterococci* (VRE), carbapenem or multidrug resistant (MDR) *Pseudomonas spp.*, carbapenem or MDR *Acinetobacter spp.*, extended-spectrum beta-lactamase (ESBL)-producing (or third generation cephalosporin resistant) *Enterobacterales*, carbapenem-resistant *Enterobacterales* (CRE).

Exclusion Criteria

- 1. Reviews, editorials, case studies, case series, letters, pre-print publications, dissertations, poster presentations.
- 2. Studies including <100 patients.
- 3. Presumed or suspected bacterial infections (rather than confirmed infections).
- 4. Studies combining bacterial and non-bacterial co-infection as a single metric.

Population

Individuals receiving care in any healthcare setting and in any age group.

Main Outcomes

The main outcome is the incidence of antimicrobial resistance in the population associated with COVID-19, either expressed as an incidence density rate (antibiotic resistant infections per 1000 patient days) or proportion (e.g. proportion of *S. aureus* that were MRSA, proportion of patient admissions with resistant infection).

Data Screening and Extraction

Records were managed using Covidence bibliographic software. All titles and abstracts were screened by a single author (in our previous review,⁴ there was substantial reviewer agreement, kappa: 0.66). Full text screening was performed by at least a single author (in the previous review, we determined kappa to be substantial at 0.62 to 0.68). A single review author extracted study characteristics and data according to a pre-defined list of study elements, with a second check by another review author. Study characteristics including design, patient population, and antimicrobial resistance metrics were extracted. We also extracted whether the authors indicated infection prevention and control (IPAC) measures were strengthened during the pandemic and/or whether there was an antimicrobial stewardship program (ASP) in place. These variables were extracted in order to stratify changes in AMR based on potential AMR-mitigating factors.

Risk of Bias Assessment

We used a 10-item validated risk of bias in prevalence studies tool incorporated into data extraction (5).

Data Analysis

Findings were summarized descriptively. In studies providing complete numerator and denominator data, incidence rate ratios (IRR) were pooled using a GLMM randomeffects meta-analysis and risk ratios (RR) were pooled using Mantel-Haenszel random effects meta-analysis with between-study variance estimated using the Paule-Mandel estimator.. Results were presented in forest plots and pooled across Gram-positive and Gram-negative organisms, stratified by the reporting of enhanced IPAC measures and/or ASP. All analyses were carried out using R version 4.1.2 with the packages *metafor* and *meta*.

Heterogeneity was assessed using the I² statistic, with <40% considered low heterogeneity, 30–60% considered moderate heterogeneity, 50–90% considered substantial heterogeneity, and 75–100% considered considerable heterogeneity.¹¹

Results

Of 6036 studies identified via literature search, 28 were eligible for inclusion (18 via full-text screening, 9 via forward citation screening, and 1 expert-identified).¹²⁻³⁹ The most common countries of origin were the United States (n=4), Italy (n=4), and Brazil (n=3).

Patient populations studied included all hospitalized patients (n=17), those hospitalized in intensive care units only (n=5), special populations (e.g., oncology, surgery) (n=3), mixed hospitalized and community-dwelling patients (n=2), and community-dwelling patients only (n=1). Studies evaluated a range of both community- and healthcareacquired infection. Combined healthcare and community-acquired infection or not setting of acquisition not distinguished was most common (n=15), followed by only healthcare-associated (n=11), and only community-acquired (n=2). The majority of studies derived resistance data from clinical specimens (n=20), six included both clinical and screening specimens or did not specify the type of specimen, followed by two studies using screening specimens only. Most studies had moderate risk of bias (n=18), followed by low (n=5), and high (n=5) risk of bias.

Measures of Antimicrobial Resistance

Incidence density (e.g., cases of resistant infections per 1000 patient days) was most commonly used to measure a change in AMR associated with COVID-19 (n=11) and proportion of isolates or infections (e.g., percentage of *S. aureus* cases that were MRSA, n=11), followed by incidence (e.g., cases per admission or discharges, n=5), and other (e.g. standardized infection ratio, point prevalence n=2). Study details and AMR metric directionality are provided in Table 1. Of the 28 eligible studies, 23 (82%) provided raw numerator and denominator data to facilitate meta-analysis.

Resistance in Gram Positive Organisms

MRSA (n=15) Over 6,848,357 patient days of follow-up, our meta-analysis found that the COVID-19 pandemic was not associated with a change in incidence rate of MRSA (IRR 1.03, 95%CI: 0.65 to 1.62, I^2 =95%, n=5). Similarly the COVID-19 pandemic was not

associated with a change in the proportion of cases that were MRSA (RR 0.91, 95%CI: 0.60 to 1.36, l^2 =93%, n=7).

VRE (n=12)

Over 356,056 patient days, meta-analysis shows that the COVID-19 pandemic was not associated with a change in the incidence of VRE (IRR 0.75, 95%CI: 0.49 to 1.15, I^2 =56%, n=3). Similarly there was no change in the proportion of VRE cases (RR 0.91, 95%CI: 0.30 to 2.79, I^2 =94%, n=5).

Overall Gram-Positive Resistance and Association with Infection Prevention and Antimicrobial Stewardship Initiatives

When pooling both MRSA and VRE, no association was found between COVID-19 pandemic and the incidence (IRR 0.99, 95%CI: 0.67 to 1.47, I^2 =91%, n=8) or proportion (RR 0.91, 95%CI: 0.55 to 1.49, I^2 =92%, n=12) of resistant Gram-positive cases. The

presence of IPAC or ASP initiatives was not associated with a statistically significant difference resistance rates (with IPAC/ASP: RR 0.59, 95%CI 0.15 to 2.42, I²=89%, n=4; without IPAC/ASP: RR: 1.15, 95%CI: 0.94 to 1.41, I²=89% n=8, test of subgroup difference P=0.36). See Figure 2 and 3.

Resistance in Gram-Negative Organisms

Resistant Acinetobacter spp. (n=8)

Across 325,847 patient days, there was no association between COVID-19 and the incidence of carbapenem- or multi-drug resistant *Acinetobacter* spp. (IRR 0.79, 95%CI: 0.30 to 2.07, I^2 =77%, n=4). However, there was a small increase in the proportion of infections that were resistant *Acinetobacter spp.* (RR 1.02, 95%CI 1.01 to 1.03, I^2 =0%, n=2).

Resistant Pseudomonas spp. (n=10)

Across 1,609,923 patient days, there was no association between COVID-19 and the incidence of resistant *Pseudomonas* infections (IRR 1.10, 95%Cl 0.91 to 1.30, $l^2=0\%$, n=4). Similarly there was no association with the proportion of cases that were resistant (RR 1.02, 95%Cl: 0.85 to 1.23, $l^2=58\%$, n=6).

ESBL (n=10)

One study with 87,204 patient days of follow-up found an increased IRR associated with the COVID-19 pandemic (IRR 15.20, 95%CI: 4.90 to 47.14). However the proportion of cases with an ESBL-producing organism was not significantly altered with COVID-19 (RR: 1.10, 95%CI: 0.91 to 1.33, I^2 =94%, n=8).

CRE (n=15)

Across 587,047 patient days, there was no significant change detected in the incidence of carbapenem-resistant *Enterobacterales* (*E. coli* and *Klebsiella spp.*) (IRR 2.05, 95%CI: 0.77 to 5.44, I^2 =95%, n=5). Similarly, there was no identified increase in proportion of cases that were CRE (RR 1.10, 95%CI: 0.61 to 1.99, I^2 =88%, n=6).

Overall Gram-Negative Resistance and Association with Infection Prevention and Antimicrobial Stewardship

When pooling all resistant Gram-negative organisms, there was a non-statistically significant association between COVID-19 pandemic and the incidence rate (IRR 1.64, 95%CI: 0.92 to 2.92, I^2 =93%, n=14) as well as the proportion of cases that were resistant (RR 1.08, 95%CI: 0.91 to 1.29, I^2 =92%, n=22). The absence of reported enhanced IPAC and/or ASP was associated with an increase in Gram-negative AMR (RR 1.11, 95%CI: 1.03 to 1.20, I^2 =88%, n=5), whereas no association was seen in

studies that did report such initiatives (RR 0.80, 95%CI: 0.38 to 1.70, I^2 =90%, n=17). However, a test for subgroup differences showed no statistically significant difference between these groups (P=0.40). Figure 4 and 5.

Discussion

Antimicrobial resistance measurement in the context of the COVID-19 pandemic is variable with substantial heterogeneity in reported outcomes. We found that although the COVID-19 pandemic was not associated with a change in Gram-positive AMR, Gram-negative resistance appears to have increased (MDR or carbapenem-resistant *Pseudomonas* or *Acinetobacter*, ESBL and CRE), particularly in settings where enhanced IPAC and ASP initiatives were not reported.

A recent special report from the US Centers for Disease Control and Prevention (CDC) found a 15% increase in the rate (per discharge or admission) of resistant organisms including carbapenem-resistant *Acinetobacter*, MRSA, CRE, and ESBL.⁸ Study location, burden of COVID-19, burden of non-COVID-19 respiratory infections, and antimicrobial prescribing practices may partially explain the difference between the CDC data and our findings. The apparent increase in Gram-negative AMR but not Gram-positive AMR suggests antibiotic prescribing may play an important role, given the high use of beta-lactam/beta-lactamase inhibitors and third generation cephalosporins in patients with COVID-19.³ Nevertheless, both the CDC report and this systematic review present a concern that the COVID-19 pandemic may play a role in increasing rates of AMR in the population.

The concern for increasing AMR in the context of COVID-19 has been previously highlighted.^{40,41} Inappropriately high usage of antibiotics in patients with COVID-19 selects for resistant organisms which can then be transmitted to the broader population.⁴¹ We have previously shown that in the context of COVID-19 co-infection and secondary infections, 38% of organisms and 61% of patients harbour AMR.⁴ This analysis extends the concern for drug resistance beyond COVID-19 infected patients themselves to document an ecologic impact of the pandemic on AMR.

The relationship between COVID-19 and AMR is complex, as several factors such as improved hand hygiene, personal protective equipment use, and physical distancing may help to reduce the transmission of AMR organisms, at least temporarily while such enhanced measures are in place.⁷ Our findings reinforce that infection prevention and control activities are important mitigating factors limiting the growth of AMR associated with COVID-19.

While this study provides a broad global view of AMR in the context of COVID-19 from an ecological perspective, there are several important limitations. There is significant heterogeneity in methodology and AMR outcome measures reported across studies. At least five different AMR metrics were provided (incidence density, incidence per admission/discharge, proportion of infections, standardized infection ratio, point prevalence), which prevents direct comparison and makes meta-analysis challenging. A lack of adjustment for confounding factors raises the possibility that changes in AMR over time may be due to changes in patient populations. And lack of longitudinal data also limits the ability to account for existing temporal trends in AMR incidence and prevalence. Many studies did not comment on other confounding factors such as the presence or intensity of their infection prevention and control or antimicrobial stewardship program, so in studies which mention these initiatives, the association with reduced AMR may represent correlation rather than causation. Several studies only reported a small number of pathogens with AMR, hence there is a risk of selective outcome reporting. It is also important to note that less than 20% of studies had low risk of bias, suggesting that higher quality studies are needed to better understand the impact of COVID-19 on AMR.

Conclusion

The COVID-19 pandemic could play an important role in the emergence and transmission of AMR, particularly for Gram-negative organisms in hospital settings. There is considerable heterogeneity in both the AMR metrics utilized and the rate of resistance reported across studies. Our findings reinforce not only the need for strengthened infection prevention and antimicrobial stewardship, but also robust and consistent AMR surveillance as part of the pandemic response and recovery.

Figure 1. PRISMA Flow Diagram




Figure 2. COVID-19 Pandemic and Gram-Positive AMR Incidence Rate Ratio

Study	Post-COVII Events Tim) Pre- e Events	-COVID Time	Incidence Rate Ratio	IRR	95%-Cl
Lo S-H, 2020 (MRSA) Ochoa-Hein E, 2021 (MRSA) Wee LEI, 2021 (MRSA) Porto APM, 2022 (MRSA) Evans ME, 2022 (MRSA) Chamieh A, 2021 (VRE) Lo S-H, 2020 (VRE) Porto APM, 2022 (VRE)	45 3500 0 1437 169 26490 21 6227 306 255323 4 5185 18 3500 7 6227	2 2 4 1194 1 9 10 5 213 2 2 10 0 62	75500 72832 020463 56425 693347 75000 75500 56425	* * *	1.01 0.55 1.90 1.52 0.58 0.63	[0.68; 1.38] [0.05; 21.11] [0.46; 0.64] [0.90; 4.04] [1.27; 1.81] [0.18; 1.84] [0.37; 1.06] [0.78; 51.55]
Common effect model Random effects model Heterogeneity: $I^2 = 91\%$, $\tau^2 = 0$.1909, <i>p</i> < 0.01			0.1 0.5 1 2 10		[0.78; 0.95] [0.67; 1.47]

*All studies included IPAC/ASP initiatives

Figure 3. COVID-19 Pandemic and Gram-Positive AMR Risk Ratio

0	Post	-COVID	Pre	-COVID				Weight	Weight	
Study	Events	Total	Events	Total	Risk Ratio	RR	95%-CI	(common)	(random)	
IPAC/ASP = Yes					1					
Bentivegna E, 2021 (MRSA)	22	483	137	1134	-	0.38	[0.24; 0.58]	0.1%	9.8%	
Tham N, 2022 (MRSA)	8	2530	8	3415	- x	1.35	[0.51; 3.59]	0.0%	7.6%	
Gisselo KL, 2022 (VRE)	12	21082	121	25130		0.12	[0.07; 0.21]	0.1%	9.3%	
Tham N, 2022 (VRE)	5	2530	2	3415		3.37	[0.66; 17.38]	0.0%	5.0%	
Common effect model		26625		33094	♦	0.29	[0.22; 0.40]	0.1%		
Random effects model						0.59	[0.15; 2.42]		31.6%	
Heterogeneity: $I^2 = 89\%$, $\tau^2 = 1$.	8181, <i>p</i> <	0.01								
IPAC/ASP = No or unknown										
Guven DC, 2021 (MRSA)	2	43	0	55		- 6.38	[0.31; 129.46]	0.0%	2.2%	
Hirabayashi A, 2021 (MRSA)	_		244500			1.01	[1.01; 1.02]	99.5%	10.7%	
McNeil MJ, 2021 (MRSA)	26	17348	125	63904		0.77	[0.50; 1.17]	0.0%	9.9%	
La Vecchia A, 2022 (MRSA)	26	99	50	156	4	0.82	[0.55; 1.22]	0.0%	10.0%	
Polemis M, 2021 (MRSA)	257	631	612	2201		1.46	[1.30; 1.64]	0.2%	10.6%	
Despotovic A, 2021 (VRE)	11	15	27	44		1.20	[0.81; 1.76]	0.0%	10.0%	
Mares C, 2022 (VRE)	2	81	3	174		1.43	[0.24; 8.40]	0.0%	4.6%	
Polemis M, 2021 (VRE)	233	973	224	1392		1.49	[1.26; 1.75]	0.1%	10.5%	
Common effect model		249190		590426		1.01	[1.01; 1.02]	99.9%		
Random effects model					\$	1.15	[0.94; 1.41]		68.4%	
Heterogeneity: $I^2 = 89\%$, $\tau^2 = 0$.	0480, <i>p</i> <	0.01								
Common effect model		275815		623520		1.01	[1.01; 1.02]	100.0%		
Random effects model					4	0.91	[0.55; 1.49]		100.0%	
Heterogeneity: $I^2 = 92\%$, $\tau^2 = 0$.	6089. p <	0.01								
Test for subgroup differences (co			64.96, df	= 1 (p < 0.00)	0011) 0.1 1 10	100				
Test for subgroup differences (re										

Test for subgroup differences (random effects): $\chi_1^2 = 0.83$, df = 1 (p = 0.36)

Figure 4. COVID-19 Pandemic and Gram-Negative AMR Incidence Rate Ratio

Study	Post Events	-COVID Time	Pr Events	e-COVID Time	Ind	cidence Ra Ratio	te	IRR	95%-CI
Study Chamieh A, 2021 (Pseudomonas) Lo S-H, 2020 (Pseudomonas) Ochoa-Hein E, 2021 (Pseudomonas) Wee LEI, 2021 (Pseudomonas) Chamieh A, 2021 (A. baumanni) Gaspar GG, 2021 (A. baumanni) Lo S-H, 2020 (A. baumanni) Ochoa-Hein E, 2021 (A. baumanni) Ochoa-Hein E, 2021 (ESBL)	5 18 2	51852 35000 14372 264904 51852 672 35000 14372 14372		75000 75500 72832 1020463 75000 619 75500	_		 	2.41 1.02 2.03 1.09 0.36 3.16 0.51 0.56	[0.58; 10.09] [0.58; 1.79] [0.39; 10.45] [0.88; 1.34] [0.10; 1.28] [1.36; 7.33] [0.26; 1.02] [0.03; 10.46]
Chamieh A, 2021 (CRE) Ochoa-Hein E, 2021 (CRE) Wee LEI, 2021 (CRE) Castro MG, 2022 (CRE) Porto APM, 2022 (CRE)	2 9 353 648 67	51852 14372 34569 25724 62279	4 8 2 1900 233 28	75000 72832 169573 24421				0.36	[4.50, 47,14] [0.08; 1.70] [4.93; 105.54] [0.81; 1.02] [2.27; 3.07] [1.39; 3.37]
Common effect model Random effects model Heterogeneity: $J^2 = 93\%$, $\tau^2 = 0.9485$, p	< 0.01			۲ 0.0	01 0.1	1	10	1.33 1.64 100	[1.24; 1.43] [0.92; 2.92]

*All studies included IPAC/ASP initiatives

Figure 5. COVID-19 Pandemic and Gram-Negative AMR Risk Ratio and Presence/Absence of IPAC/ASP

Study	Post-COVI Events Tota	D Pr I Events	e-COVID Total	Risk Ratio	RR	95%-CI	Weight (common)	Weight (random)
IPAC/ASP = Yes Bentivegna E, 2021 (Pseudomonas) Lemenand O, 2021 (ESBL)	4 38 7517 25938		1134 505945		0.47 0.94	[0.17; 1.35] [0.92; 0.97]	0.0% 8.6%	2.0% 6.5%
Tham N, 2022 (ESBL)	16 253		3415		3.09	[1.27; 7.49]	0.0%	2.5%
Wardoyo EH, 2021 (ESBL)	44 6		148	4	0.91	[0.76; 1.08]	0.1%	6.1%
Micozzi A, 2021 (CRE)	19 12		80	-#-	0.29	[0.19; 0.47]	0.0%	4.5%
Common effect model	26248	7	510722			[0.92; 0.97]	8.7%	
Random effects model Heterogeneity: $I^2 = 88\%$, $\tau^2 = 0.6321$, p	- 0.01				0.80	[0.38; 1.70]		21.5%
Heterogeneity. $T = 66\%$, $t = 0.0521$, p	< 0.01							
IPAC/ASP = No or unknown								
Despotovic A, 2021 (Pseudomonas)	20 2	2 35	42	\$	1.09	[0.90; 1.32]	0.0%	6.0%
Hirabayashi A, 2021 (Pseudomonas)	14000 11650	0 28000	245000	0	1.05	[1.03; 1.07]	14.7%	6.5%
Tizkam HH, 2020 (Pseudomonas)	_	4 14	39		1.39	[0.48; 4.04]	0.0%	1.9%
Mares C, 2022 (Pseudomonas)	-	7 0	10		- 9.80	[0.59; 162.96]	0.0%	0.4%
Polemis M, 2021 (Pseudomonas)	514 116		2854	ų.	0.95	[0.88; 1.02]	0.6%	6.4%
Despotovic A, 2021 (Acinetobacter)	115 11		58		1.02	[0.98; 1.05]	0.1%	6.4%
Polemis M, 2021 (Acinetobacter)	2197 225		3133	0	1.02	[1.01; 1.03]	2.0%	6.5%
Despotovic A, 2021 (ESBL)	8 1		56		0.86	[0.63; 1.18]	0.0%	5.4%
Guven DC, 2021 (ESBL)	12 4		55	- -	1.28	[0.64; 2.56]	0.0%	3.3%
Hirabayashi A, 2021 (ESBL)	72000 36850		767000	ų.	1.09	[1.09; 1.10]	72.6%	6.5%
Tizkam HH, 2020 (ESBL)	28 3		158	P	1.23	[1.00; 1.50]	0.0%	6.0%
Mares C, 2022 (ESBL)	102 73		1149		1.36	[1.06; 1.75]	0.1%	5.7%
Despotovic A, 2021 (CRE)	20 2		51	-	1.63	[1.18; 2.26]	0.0%	5.3%
Guven DC, 2021 (CRE)	1 4		55			[0.08; 19.87]	0.0%	0.4%
Tizkam HH, 2020 (CRE)	3 1		172		1.79	[0.59; 5.44]	0.0%	1.8%
Mares C, 2022 (CRE)	22 41		636	-	1.77	[0.97; 3.22]	0.0%	3.7%
Polemis M, 2021 (CRE)	1063 193		4085	1	1.21	[1.15; 1.27]	1.0%	6.4%
Common effect model	49183	2	1024553			[1.08; 1.09]	91.3%	
Random effects model				P	1.11	[1.03; 1.20]		78.5%
Heterogeneity: $I^2 = 90\%$, $\tau^2 = 0.0133$, p	< 0.01							
Common effect model	75431	9	1535275		1.07	[1.07; 1.08]	100.0%	
Random effects model					1.08	[0.91; 1.29]		100.0%
Heterogeneity: $l^2 = 92\%$, $\tau^2 = 0.1271$, p	< 0.01							
Test for subgroup differences (common	effect): $\chi_{1}^{2} = 102.8$	0, df = 1 (p)	< 0.01)	0.01 0.1 1 10 10	0			

0.01) 0.01 0.1 1 Test for subgroup differences (common effect): $\chi_1^c = 102.80$, df = 1 (p < 0.01Test for subgroup differences (random effects): $\chi_1^2 = 0.70$, df = 1 (p = 0.40)

Author Veen Origina	0	Healthcare					Risk of Bias				
Author, Year	Country	Setting	Acquisition	AMR measure	MRSA	VRE	PsA	Abau	ESBL	CRE	
Baker MA, 2021	United States	All Hospitalized	Healthcare-Acquired	Incidence per COVID rate	↑	1					moderate
Belvisi V, 2021	Italy	ICU Only	Not specified	Point prevalence, incidence						1	high
Bentivegna E, 2021	Italy	All Hospitalized	Healthcare-Acquired	Incidence	↓		Ļ				high
Castro MG, 2022	Argentina	All Hospitalized	Both	Incidence density						1	moderate
Chamieh A, 2021	Lebanon	All Hospitalized	Both	Incidence density		Ļ	1	↓		\downarrow	moderate
Despotovic A, 2021	Serbia	ICU Only	Healthcare-Acquired	Proportion		1	1	1	\downarrow	1	moderate
Evans ME, 2022	United States	All Hospitalized	Healthcare-Acquired	Incidence density	1						Moderate
Gaspar GG, 2021	Brazil	ICU Only	Not specified	Incidence density				1			moderate
Gisselo KL, 2022	Denmark	All Hospitalized	Healthcare-Acquired	Incidence		Ļ					low
Guven DC, 2021	Turkey	Palliative oncology	Healthcare-Acquired	Proportion	1				1	↑	moderate
Hirabayashi A, 2021	Japan	All Hospitalized	Both	Proportion	1		1		1		moderate
Jeon K, 2022	South Korea	ICU Only	Both	Incidence density	↓	1	Ļ	J		↑	moderate
La Vecchia A, 2022	Italy	All Hospitalized	Both	Proportion	↓						moderate
Lemenand O, 2021	France	Community	Community-	Proportion					Ļ		low
Lo S-H, 2020	Taiwan	All Hospitalized	Not specified	Incidence density	↓	Ļ	1	J			moderate
Mares C, 2022	Romania	Hospitalized/non-Hosp	Both	Proportion		1	1		1	1	moderate
McNeil MJ, 2021	United States	All Hospitalized	Community-	Incidence	↓						moderate
Micozzi A, 2021	Italy	Malignant hematology	Both	Proportion						\downarrow	low
O'Riordan F, 2022	Ireland	All Hospitalized	Both	Proportion		Ļ			Ļ	1	high
Ochoa-Hein E, 2021	Mexico	All Hospitalized	Healthcare-Acquired	Incidence density	↓		1	J	1	1	moderate
Polemis M, 2021	Greece	All Hospitalized	Both	Proportion	1	1	Ļ	↑		1	moderate
Polly M, 2022	Brazil	All Hospitalized	Healthcare-Acquired	Incidence density	1	Ļ	Ļ	1		↑	moderate
Porto APM, 2022	Brazil	ICU Only	Healthcare-Acquired	Incidence density	1	1				↑	low
Tham N, 2022	Australia	Surgical	Healthcare-Acquired	Incidence	1	1			↑		moderate
Tizkam HH, 2020	Iraq	All Hospitalized	Not specified	Proportion			1		1	1	high
Wardoyo EH, 2021	Indonesia	Hospitalized/non-Hosp	Not specified	Proportion					\downarrow		high
Wee LEI, 2021	Singapore	All Hospitalized	Both	Incidence density	\downarrow		1			\downarrow	low
Weiner-Lastinger LM,	United States	All Hospitalized	Healthcare-Acquired	standardized infection ratio	1						moderate

Table 1. AMR Associated with COVID-19 Study Characteristics

*Directionality refers to numerical change in AMR during COVID-19 compared to before the pandemic, MRSA: methicillin-resistant *S. aureus*, VRE: Vancomycin-resistant Enterococcus, PsA: MDR or carbapenem-resistant *Pseudomonas aeruginosa*, Abau: MDR or carbapenem-resistant *Acinetobacter baumannii*, ESBL: extended-spectrum beta-lactamase producing organism, CRE: carbapenem-resistant *Enterobacterales*

References

- Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical Microbiology and Infection. 2020;26:1622– 9.
- Langford BJ, So M, Leung V, Raybardhan S, Lo J, Kan T, et al. Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. Clinical Microbiology and Infection. 2021;S1198743X21006364.
- 3. Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clinical Microbiology and Infection. 2021;27:520–31.
- Langford BJ, So M, Simeonova M, Leung V, Lo J, Kan T, et al. Antimicrobial Resistance in Patients with COVID-19: A Systematic Review and Meta-Analysis. SSRN Journal [Internet]. 2022 [cited 2022 May 12]; Available from: https://www.ssrn.com/abstract=4099404
- 5. Buehrle DJ, Wagener MM, Nguyen MH, Clancy CJ. Trends in Outpatient Antibiotic Prescriptions in the United States During the COVID-19 Pandemic in 2020. JAMA Netw Open. 2021;4:e2126114.
- 6. Kitano T, Brown KA, Daneman N, MacFadden DR, Langford BJ, Leung V, et al. The Impact of COVID-19 on Outpatient Antibiotic Prescriptions in Ontario, Canada; An Interrupted Time Series Analysis. Open Forum Infectious Diseases. 2021;8:ofab533.
- 7. Collignon P, Beggs JJ. CON: COVID-19 will not result in increased antimicrobial resistance prevalence. JAC-Antimicrobial Resistance. 2020;2:dlaa051.
- US Centers for Disease Control and Prevention. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022 [Internet]. National Center for Emerging and Zoonotic Infectious Diseases; 2022 Jun [cited 2022 Aug 9]. Available from: https://stacks.cdc.gov/view/cdc/117915
- 9. World Health Organization. WHO Research Database [Internet]. Geneva, Switzerland; 2021. Available from: https://search.bvsalud.org/global-literature-onnovel-coronavirus-2019-ncov/
- Briscoe S, Bethel A, Rogers M. Conduct and reporting of citation searching in Cochrane systematic reviews: A cross-sectional study. Res Syn Meth. 2020;11:169– 80.
- 11. Deeks J, Higgins J, Altman D. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Available from: https://training.cochrane.org/handbook

- 12. Baker MA, Sands KE, Huang SS, Kleinman K, Septimus EJ, Varma N, et al. The Impact of Coronavirus Disease 2019 (COVID-19) on Healthcare-Associated Infections. Clinical Infectious Diseases. 2021;ciab688.
- Belvisi V, Del Borgo C, Vita S, Redaelli P, Dolce P, Pacella D, et al. Impact of SARS CoV-2 pandemic on carbapenemase-producing Klebsiella pneumoniae prevention and control programme: convergent or divergent action? Journal of Hospital Infection. 2021;109:29–31.
- 14. Bentivegna E, Luciani M, Arcari L, Santino I, Simmaco M, Martelletti P. Reduction of Multidrug-Resistant (MDR) Bacterial Infections during the COVID-19 Pandemic: A Retrospective Study. IJERPH. 2021;18:1003.
- 15. Castro MG, Ubiergo L, Vicino M, Cuevas G, Argarañá F. Rising incidence of carbapenem resistant isolates: an Argentinian hospital's experience. More trouble in the aftermath of the COVID-19 pandemic. Iberoamerican Journal of Medicine. 2022;4:92–9.
- Chamieh A, Zgheib R, El-Sawalhi S, Yammine L, El-Hajj G, Zmerli O, et al. Trends of Multidrug-Resistant Pathogens, Difficult to Treat Bloodstream Infections, and Antimicrobial Consumption at a Tertiary Care Center in Lebanon from 2015– 2020: COVID-19 Aftermath. Antibiotics. 2021;10:1016.
- 17. Despotovic A, Milosevic B, Cirkovic A, Vujovic A, Cucanic K, Cucanic T, et al. The Impact of COVID-19 on the Profile of Hospital-Acquired Infections in Adult Intensive Care Units. Antibiotics. 2021;10:1146.
- Evans ME, Simbartl LA, Kralovic SM, Clifton M, DeRoos K, McCauley BP, et al. Healthcare-associated infections in Veterans Affairs acute-care and long-term healthcare facilities during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol. 2022;1–7.
- 19. Gaspar GG, Ferreira LR, Feliciano CS, Campos Júnior CP, Molina FMR, Vendruscolo ACS, et al. Pre- and post-COVID-19 evaluation of antimicrobial susceptibility for healthcare-associated infections in the intensive care unit of a tertiary hospital. Rev Soc Bras Med Trop. 2021;54:e0090-2021.
- 20. Gisselø KL, Rubin IMC, Knudsen MS, From-Hansen M, Stangerup M, Kavalaris CP, et al. Substantial Decrease in Vancomycin-Resistant *Enterococcus faecium* Outbreak Duration and Number of Patients During the Danish COVID-19 Lockdown: A Prospective Observational Study. Microbial Drug Resistance. 2022;28:73–80.
- 21. Guven DC, Eroglu I, Ismayilov R, Ulusoydan E, Aktepe OH, Telli Dizman G, et al. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards. J Oncol Pharm Pract. 2021;107815522110438.

- 22. Hirabayashi A, Kajihara T, Yahara K, Shibayama K, Sugai M. Impact of the COVID-19 pandemic on the surveillance of antimicrobial resistance. Journal of Hospital Infection. 2021;117:147–56.
- 23. Jeon K, Jeong S, Lee N, Park MJ, Song W, Kim HS, et al. Impact of COVID-19 on Antimicrobial Consumption and Spread of Multidrug-Resistance in Bacterial Infections. Antibiotics. 2022;11:535.
- 24. La Vecchia A, Ippolito G, Taccani V, Gatti E, Bono P, Bettocchi S, et al. Epidemiology and antimicrobial susceptibility of Staphylococcus aureus in children in a tertiary care pediatric hospital in Milan, Italy, 2017—2021. Ital J Pediatr. 2022;48:67.
- Lemenand O, Coeffic T, Thibaut S, Colomb Cotinat M, Caillon J, Birgand G. Decreasing proportion of extended-spectrum beta-lactamase among E. coli infections during the COVID-19 pandemic in France. Journal of Infection. 2021;83:664–70.
- 26. Lo SH, Lin CY, Hung CT, He JJ, Lu PL. The impact of universal face masking and enhanced hand hygiene for COVID-19 disease prevention on the incidence of hospital-acquired infections in a Taiwanese hospital. International Journal of Infectious Diseases. 2021;104:15–8.
- 27. Mare ⊂ C, Petca RC, Petca A, Popescu RI, Jinga V. Does the COVID Pandemic Modify the Antibiotic Resistance of Uropathogens in Female Patients? A New Storm? Antibiotics. 2022;11:376.
- McNeil JC, Flores AR, Kaplan SL, Hulten KG. The Indirect Impact of the SARS-CoV-2 Pandemic on Invasive Group a Streptococcus, Streptococcus Pneumoniae and Staphylococcus Aureus Infections in Houston Area Children. Pediatric Infectious Disease Journal. 2021;40:e313–6.
- 29. Micozzi A, Assanto GM, Cesini L, Minotti C, Cartoni C, Capria S, et al. Reduced transmission of *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* (KPC-KP) in patients with haematological malignancies hospitalized in an Italian hospital during the COVID-19 pandemic. JAC-Antimicrobial Resistance. 2021;3:dlab167.
- 30. O'Riordan F, Shiely F, Byrne S, O'Brien D, Ronayne A, Fleming A. Antimicrobial use and antimicrobial resistance in Enterobacterales and Enterococcus faecium: a time series analysis. Journal of Hospital Infection. 2022;120:57–64.
- 31. Ochoa-Hein E, González-Lara MF, Chávez-Ríos AR, de-Paz-García R, Haro-Osnaya A, González-González R, et al. Surge in Ventilator-Associated Pneumonias and Bloodstream Infections in An Academic Referral Center Converted to Treat COVID-19 Patients. RIC. 2021;73:6588.

- Polemis M, Mandilara G, Pappa O, Argyropoulou A, Perivolioti E, Koudoumnakis N, et al. COVID-19 and Antimicrobial Resistance: Data from the Greek Electronic System for the Surveillance of Antimicrobial Resistance—WHONET-Greece (January 2018–March 2021). Life. 2021;11:996.
- 33. Polly M, de Almeida BL, Lennon RP, Cortês MF, Costa SF, Guimarães T. Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil. American Journal of Infection Control. 2022;50:32–8.
- 34. Porto APM, Borges IC, Buss L, Machado A, Bassetti BR, Cocentino B, et al. Healthcare-associated infections on the intensive care unit in 21 Brazilian hospitals during the early months of the coronavirus disease 2019 (COVID-19) pandemic: An ecological study. Infect Control Hosp Epidemiol. 2022;1–7.
- 35. Tham N, Fazio T, Johnson D, Skandarajah A, Hayes IP. Hospital Acquired Infections in Surgical Patients: Impact of COVID-19-Related Infection Prevention Measures. World J Surg. 2022;46:1249–58.
- 36. Tizkam HH, Fadhil OQ, Ghazy E. Effect of COVID-19 on bacterial resistance. Systematic Reviews in Pharmacy. 2020;11:423–7.
- 37. Wee LEI, Conceicao EP, Tan JY, Magesparan KD, Amin IBM, Ismail BBS, et al. Unintended consequences of infection prevention and control measures during COVID-19 pandemic. American Journal of Infection Control. 2021;49:469–77.
- 38. Wardoyo EH, Suardana IW, Yasa IWPS, Sukrama IDM. Antibiotics susceptibility of Escherichia coli isolates from clinical specimens before and during COVID-19 pandemic. Iranian Journal of Microbiology. 2021;13:156.
- 39. Weiner-Lastinger LM, Pattabiraman V, Konnor RY, Patel PR, Wong E, Xu SY, et al. The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: A summary of data reported to the National Healthcare Safety Network. Infect Control Hosp Epidemiol. 2022;43:12–25.
- 40. Nieuwlaat R, Mbuagbaw L, Mertz D, Burrows LL, Bowdish DME, Moja L, et al. Coronavirus Disease 2019 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies. Clinical Infectious Diseases. 2021;72:1657–9.
- 41. Clancy CJ, Buehrle DJ, Nguyen MH. PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. JAC-Antimicrobial Resistance. 2020;2:dlaa049.